Top Wall Street Forecasters Revamp Beyond Air Expectations Ahead Of Q4 Earnings

Beyond Air, Inc. XAIR will release its fourth-quarter financial results after the closing bell on Tuesday, June 17.

Analysts expect the Garden City, New York-based company to report quarterly revenue of $1.39 million, compared to $470,000 a year earlier, according to data from Benzinga Pro.

On April 21, Beyond Air announced its NeuroNOS subsidiary was granted an FDA Orphan Drug Designation.

Beyond Air shares fell 3% to close at $0.1779 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

Today's Best Finance Deals

BTIG analyst Marie Thibault downgraded the stock from Buy to Neutral on June 25, 2024. This analyst has an accuracy rate of 63%.
Truist Securities analyst Gregory Fraser maintained a Buy rating and lowered the price target from $10 to $8 on April 30, 2024. This analyst has an accuracy rate of 63%.

Considering buying XAIR stock? Here’s what analysts think: